NTLA Intellia Therapeutics Inc

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.

$88.50  +6.98 (8.56%)
As of 01/24/2022 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/06/2016
Outstanding shares:  73,487,046
Average volume:  930,361
Market cap:   $6,071,499,741
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYZM6C2
Valuation   (See tab for details)
PE ratio:   -26.18
PB ratio:   5.47
PS ratio:   226.60
Return on equity:   -20.67%
Net income %:   -854.10%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy